Straits Times Index
3,110.73 +36.47 (+1.19%) Nikkei
32,307.86 -550.45 (-1.68%) Hang Seng
16,334.37 -11.52 (-0.07%) FTSE 100
7,554.47 +40.75 (+0.54%) Bitcoin USD
44,184.61 +896.77 (+2.07%) CMC Crypto 200
914.81 +18.10 (+2.02%)
Aprea Therapeutics, Inc. (APRE)
| Previous close | 3.6500 |
| Open | 3.7450 |
| Bid | 3.6400 x 1300 |
| Ask | 3.8400 x 1000 |
| Day's range | 3.5817 - 3.8099 |
| 52-week range | 0.4740 - 12.0000 |
| Volume | |
| Avg. volume | 10,403 |
| Market cap | 13.77M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 0.30 |
| EPS (TTM) | 12.3100 |
| Earnings date | 09 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireAprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
DOYLESTOWN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the three and nine months ended September 30, 2023, and provided a business update. “We are very pleased by the progress of our diversified programs this past quarter. Importantly, we presented initial clinical data from our Phase 1/2a study
- GlobeNewswire
Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
Event featuring Fiona Simpkins, M.D. and Timothy A. Yap, MBBS, PhD, FRCP to take place on October 31, 2023 at 11:00 am ETDOYLESTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced it will host a KOL event on Tuesday, October 31, 2023 at 11:00 am ET. The program will feature Dr. Fiona Simpkins, Perelman School of Medicin
ZacksBears are Losing Control Over Aprea Therapeutics, Inc. (APRE), Here's Why It's a 'Buy' Now
Aprea Therapeutics, Inc. (APRE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
